Cancer

PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISight® Digital Pathology Platform and Co-Develop New AI Diagnostics

Collaboration includes use of PathAI’s AISight®¹ digital pathology image management system at Northwestern Medicine and joint efforts in research, clinical…

7 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression

SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…

7 months ago

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations…

7 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing…

7 months ago

Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics…

7 months ago

Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025

Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical…

7 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7…

7 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed…

7 months ago

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Montreal, Quebec--(Newsfile Corp. - June 2, 2025) -  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),…

7 months ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year…

7 months ago